70
Participants
Start Date
March 25, 2019
Primary Completion Date
May 7, 2021
Study Completion Date
May 11, 2022
Itacitinib
for up to 56 days
The Mount Sinai Hospital, New York
Children's Hospital of Philadelphia, Philadelphia
University of Pennsylvania, Abramson Cancer Center, Philadelphia
Emory University, Atlanta
Children's Healthcare of Atlanta, Atlanta
Vanderbilt University, Nashville
Ohio State University, Columbus
Mayo Clinic, Rochester
University of Kansas Cancer Center, Fairway
MD Anderson Cancer Center, Houston
Children's Hospital of Los Angeles, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
Fred Hutchinson Cancer Research Center, Seattle
Massachusetts General Hospital, Boston
John Levine
OTHER